PolyPeptide Is Said to Attract Takeover Interest From EQT, KKR
Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private equity firms including EQT AB and KKR & Co., people with knowledge of the matter said.
By Dinesh Nair, Allegra Catelli, Manuel Baigorri · Bloomberg
Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private equity firms including EQT AB and KKR & Co., people with knowledge of the matter said.